[Federal Register Volume 88, Number 118 (Wednesday, June 21, 2023)]
[Notices]
[Pages 40273-40275]
[FR Doc No: 2023-13134]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2022-D-2275]

Oncology Drug Products Used With Certain In Vitro Diagnostic
Tests: Pilot Program; Guidance for Industry, Clinical Laboratories, and
Food and Drug Administration Staff; Availability

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice of availability.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA or Agency) is announcing
the availability of a final guidance for industry, clinical
laboratories, and FDA staff entitled ``Oncology Drug Products Used with
Certain In Vitro Diagnostic Tests: Pilot Program.'' FDA is issuing this
guidance to announce and describe FDA's voluntary pilot program for
certain oncology drug products regulated by FDA's Center for Drug
Evaluation and Research (CDER) used with certain in vitro diagnostic
tests. FDA intends to pilot a new approach to provide greater
transparency regarding performance characteristics that certain tests
for oncology biomarkers should meet. Through this transparency FDA
seeks to support better and more consistent performance of certain
laboratory-developed tests (LDTs) used to identify patients for
treatment with certain oncology drug products, resulting in better drug
selection and improved care for patients with cancer. The guidance has
been implemented without prior comment, but remains subject to comment
in accordance with the Agency's good guidance practices.

DATES: The announcement of the guidance is published in the Federal
Register on June 21, 2023.

ADDRESSES: You may submit either electronic or written comments on
Agency guidances at any time as follows:

Electronic Submissions

    Submit electronic comments in the following way:
     Federal eRulemaking Portal: https://www.regulations.gov.
Follow the instructions for submitting comments. Comments submitted
electronically, including attachments, to https://www.regulations.gov
will be posted to the docket unchanged. Because your comment will be
made public, you are solely responsible for ensuring that your comment
does not include any confidential information that you or a third party
may not wish to be posted, such as medical information, your or anyone
else's Social Security number, or confidential business information,
such as a manufacturing process. Please note that if you include your
name, contact information, or other information that identifies you in
the body of your comments, that information will be posted on https://www.regulations.gov.
     If you want to submit a comment with confidential
information that you do not wish to be made available to the public,
submit the comment as a written/paper submission and in the manner
detailed (see ``Written/Paper Submissions'' and ``Instructions'').

Written/Paper Submissions

    Submit written/paper submissions as follows:
     Mail/Hand Delivery/Courier (for written/paper
submissions): Dockets Management Staff (HFA-305), Food and Drug
Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
     For written/paper comments submitted to the Dockets
Management Staff, FDA will post your comment, as well as any
attachments, except for information submitted, marked and identified,
as confidential, if submitted as detailed in ``Instructions.''
    Instructions: All submissions received must include the Docket No.
FDA-2022-D-2275 for ``Oncology Drug Products Used with Certain In Vitro
Diagnostic Tests: Pilot Program.'' Received comments will be placed in
the docket and, except for those submitted as ``Confidential
Submissions,'' publicly viewable at https://www.regulations.gov or at
the Dockets Management Staff between 9 a.m. and 4 p.m., Monday through
Friday,<PHONE_NUMBER>.
     Confidential Submissions--To submit a comment with
confidential information that you do not wish to be made publicly
available, submit your comments only as a written/paper submission. You
should submit two copies total. One copy will include the information
you claim to be confidential with a heading or cover note that states
``THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.'' The Agency will
review this copy, including the claimed confidential information, in
its consideration of comments. The second copy, which will have the
claimed confidential information redacted/blacked out, will be
available for public viewing and posted on https://www.regulations.gov.
Submit both copies to the Dockets Management Staff. If you do not wish
your name and contact information to be made publicly available, you
can provide this information on the cover sheet and not in the body of
your comments and you must identify this information as
``confidential.'' Any information marked as ``confidential'' will not
be disclosed except in accordance with 21 CFR 10.20 and other
applicable disclosure law. For more information about FDA's posting of
comments to public dockets, see 80 FR 56469, September 18, 2015, or
access the information at: https://www.govinfo.gov/content/pkg/FR-2015-09-18/pdf/2015-23389.pdf.
    Docket: For access to the docket to read background documents or
the electronic and written/paper comments received, go to https://www.regulations.gov and insert the docket number, found in brackets in
the heading of this document, into the ``Search'' box and follow the
prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane,
Rm. 1061, Rockville, MD 20852,<PHONE_NUMBER>.
    You may submit comments on any guidance at any time (see 21 CFR
10.115(g)(5)).
    An electronic copy of the guidance document is available for
download from the internet. See the SUPPLEMENTARY INFORMATION section
for information on electronic access to the guidance. Submit written
requests for single copies of the guidance to the Division of Drug
Information, Center for Drug Evaluation and Research, Food and Drug
Administration, 10001 New Hampshire Ave., Hillandale Building, 4th
Floor, Silver Spring, MD 20993-0002; or to the Office of Policy, Center
for Devices and Radiological Health, Food and Drug Administration,
10903 New Hampshire Ave., Bldg. 66, Rm. 5431, Silver Spring, MD 20993-
0002. Send one self-addressed adhesive label to assist that office in
processing your request.

FOR FURTHER INFORMATION CONTACT: Brittany Schuck, Center for Devices
and Radiological Health, Food and Drug Administration, 10903 New
Hampshire Ave., Bldg. 66, Rm. 5422, Silver Spring, MD 20993-0002, 301-
796-5199 or Reena Philip, Oncology Center of Excellence, Food and Drug
Administration, 10903 New Hampshire Ave., Silver Spring, MD 20993, 301-
796-6179.

SUPPLEMENTARY INFORMATION:

I. Background

    We are announcing the availability of a guidance for industry,
clinical laboratories, and FDA staff entitled ``Oncology Drug Products
Used with Certain In Vitro Diagnostic Tests: Pilot Program.'' We are
issuing this guidance consistent with our good guidance practices (GGP)
regulation (Sec.  10.115 (21 CFR 10.115)). We are implementing this
guidance without prior public comment because we have determined that
prior public participation is not feasible or appropriate (Sec.
10.115(g)(2)). The pilot is intended to provide greater transparency
regarding performance characteristics that certain tests for oncology
biomarkers should meet. Although this guidance document is being
implemented without prior public comment, it remains subject to comment
in accordance with FDA's GGP regulation.
    An in vitro companion diagnostic test (also known as an in vitro
companion diagnostic device) provides information that is essential for
the safe and effective use of a corresponding therapeutic product. FDA
is issuing this guidance to announce and describe FDA's voluntary pilot
program for drug product sponsors with regard to certain CDER-regulated
oncology drug products for which FDA determines that use of an in vitro
diagnostic test is needed to identify the intended patient population,
and corresponding clinical trial assay(s) that use the same technology
as a previously FDA-authorized companion diagnostic test for any
indication for which there is a well-validated reference method, well-
validated comparator method, and/or well-characterized materials that
can be used to support test accuracy. This pilot is intended for tests
for which FDA believes it is appropriate to extrapolate clinical
validity of the test(s) used to select patients in a drug trial to
other tests of the same type with similar analytical performance. In
this pilot, FDA will evaluate no more than nine sponsors for possible
acceptance into the pilot based on evaluation of the factors described
in the guidance. Sponsors who are interested in being considered for
the voluntary pilot program and who affirm their commitment to provide
information set forth in the guidance if FDA subsequently requests that
they do so should submit correspondence titled ``Statement of interest
in participation in the Oncology Drug Products Used with Certain In
Vitro Diagnostic Tests: Pilot Program'' to their Investigational New
Drug (IND) applications, New Drug Applications (NDA), or Biologic
License Applications (BLA), as appropriate.
    Under this pilot, if FDA concludes that the drug product meets the
applicable standards for its approval, FDA intends to rely on the same
pivotal clinical trial(s) that support approval of the drug product to
establish the clinical validity for the clinical trial assays (CTAs)
used in those trial(s). Further, FDA intends to recommend minimum
analytical performance characteristics for other tests that, when
established through properly conducted validation studies, FDA believes
would support extrapolation of the clinical validity of the CTA(s) to
additional tests of the same type. If FDA approves an oncology drug
product enrolled in this pilot program, FDA intends to recommend
minimum performance characteristics for in vitro diagnostic tests to
identify patients for treatment with those drug products, and make this
information publicly available on FDA's website.
    The guidance represents the current thinking of FDA on ``Oncology
Drug Products Used with Certain In Vitro Diagnostic Tests: Pilot
Program.'' It does not establish any rights for any person and is not
binding on FDA or the public. You can use an alternative approach if it
satisfies the requirements of the applicable statutes and regulations.

II. Electronic Access

    Persons interested in obtaining a copy of the guidance may do so by
downloading an electronic copy from the internet. A search capability
for all Center for Devices and Radiological Health guidance documents
is available at https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/guidance-documents-medical-devices-and-radiation-emitting-products. This guidance document is also
available at https://www.regulations.gov, https://www.fda.gov/regulatory-information/search-fda-guidance-documents, or https://www.fda.gov/drugs/guidance-compliance-regulatory-information/guidances-drugs. Persons unable to download an electronic copy of ``Oncology Drug
Products Used with Certain In Vitro Diagnostic Tests: Pilot Program''
may send an email request to [email protected] to receive an
electronic copy of the document. Please use the document number 22001
and complete title to identify the guidance you are requesting.

III. Paperwork Reduction Act of 1995

    For this pilot, FDA will request information from no more than 9
sponsors. Initial statements of interest from sponsors interested in
being evaluated for participation in the pilot, as described in the
guidance, are not ``information'' in accordance with 5 CFR
1320.3(h)(1). Thus, this guidance contains no new collection of
information.
    While this guidance contains no new collection of information, to
the extent the guidance does refer to previously approved FDA
collections of information, clearance by the Office of Management and
Budget (OMB) under the Paperwork Reduction Act of 1995 (PRA) (44 U.S.C.
3501-3521) is not required for this guidance. The previously approved
collections of information are subject to review by OMB under the PRA.
The collections of information in the following FDA regulations,
guidance, and forms have been approved by OMB as listed in the
following table:

------------------------------------------------------------------------
 21 CFR part; guidance; or FDA
             form                       Topic           OMB control No.
------------------------------------------------------------------------
807, subpart E................  Premarket                      0910-0120
                                 notification.
814, subparts A through E.....  Premarket approval...          0910-0231
860, subpart D................  De Novo                        0910-0844
                                 classification
                                 process.
312...........................  Investigational new            0910-0014
                                 drug applications.
314...........................  New drug applications          0910-0001
601...........................  Biologic license               0910-0338
                                 applications.
------------------------------------------------------------------------

    Dated: June 14, 2023.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2023-13134 Filed 6-20-23; 8:45 am]
BILLING CODE 4164-01-P


[Federal Register: September 15, 2006 (Volume 71, Number 179)]
[Notices]
[Page 54481-54482]
[DOCID:fr15se06-43]

-----------------------------------------------------------------------

ENVIRONMENTAL PROTECTION AGENCY

[FRL-8220-2; EPA-HQ-Docket ID No. EPA-ORD-2006-0666]

Approaches To Estimating the Waterborne Disease Outbreak Burden
in the United States: Uses and Limitations of the Waterborne Disease
Outbreak Surveillance System; External Review Draft

AGENCY: Environmental Protection Agency (EPA).

ACTION: Notice of public comment period.

-----------------------------------------------------------------------

SUMMARY: EPA is announcing a 30-day public comment period for the draft
document titled, Approaches To Estimating the Waterborne Disease
Outbreak Burden in the United States: Uses and Limitations of the
Waterborne Disease Outbreak Surveillance System (EPA/600/R-06/069). The
document was prepared by the National Center for Environmental
Assessment (NCEA) within EPA's Office of Research and Development.
    EPA is releasing this draft document solely for the purpose of pre-
dissemination peer review under applicable information quality
guidelines. This document has not been formally disseminated by EPA. It
does not represent and should not be construed to represent any Agency
policy or determination. EPA will consider any public comments
submitted in accordance with this notice when revising the document.

DATES: The 30-day public comment period begins September 15, 2006, and
ends October 16, 2006. Technical comments should be in writing and must
be received by EPA by October 16, 2006.

ADDRESSES: The draft Approaches To Estimating the Waterborne Disease
Outbreak Burden in the United States: Uses and Limitations of the
Waterborne Disease Outbreak Surveillance System (EPA/600/R-06/069) is
available primarily via the Internet on the National Center for
Environmental Assessment's home page under the Recent Additions and
Publications menus at http://www.epa.gov/ncea. A limited number of

paper copies are available from Ms. Donna Tucker, Technical Information
Manager, NCEA-Cincinnati; telephone:<PHONE_NUMBER>; facsimile: 513-569-
7916; e-mail<EMAIL_ADDRESS>If you are requesting a paper copy,
please provide your name, your mailing address, and the document title,
Approaches To Estimating the Waterborne Disease Outbreak Burden in the
United States: Uses and Limitations of the Waterborne Disease Outbreak
Surveillance System (EPA/600/R-06/069).
    Comments may be submitted electronically via EPA's E-Docket, by
mail, by facsimile, or by hand delivery/courier. Please follow the
detailed instructions provided in the Supplementary Information section
of this notice.

FOR FURTHER INFORMATION CONTACT: For information on the public comment
period, contact the Office of Environmental Information Docket;
telephone:<PHONE_NUMBER>; facsimile:<PHONE_NUMBER>; or e-mail:
<EMAIL_ADDRESS>
    For technical information, contact Glenn Rice, NCEA; telephone:
513-569-7813; facsimile:<PHONE_NUMBER>; or e-mail<EMAIL_ADDRESS>
SUPPLEMENTARY INFORMATION:

I. Information About the Project/Document

    Information about waterborne disease outbreaks (WBDOs) in the
United States is voluntarily reported by State, territorial and local
public health agencies to the Centers for Disease Control and
Prevention (CDC). CDC and EPA jointly maintain a WBDO database. The
database describes outbreak attributes including, among other things,
the drinking water system deficiency, the etiologic agent, and the
number of individuals who became ill. Underreporting of such events is
assumed but the magnitude of underreporting is unknown.
    This draft document presents an approach for estimating the
epidemiologic and economic burden of disease associated with 665 WBDOs
reported in the U.S. between 1971 and 2000. The term disease burden
broadly refers to the magnitude of the impact incurred by society as a
consequence of disease in the community (e.g., decrements in a
population's health or the associated economic effects) and there are
various metrics that can be employed by analysts to quantify burden. In
order to capture some of the benefits of drinking water regulations,
EPA has typically expressed waterborne disease impacts in terms of
epidemiologic and monetary measures; this WBDO burden analysis employs
those same measures. Because not all WBDOs in the United States and
associated cases of illness are reported, the WBDO database on which
this draft document is based is not comprehensive. The extent to which
WBDOs are not recognized is unknown and is not examined in this
analysis. This draft report develops several quantitative sensitivity
analyses to characterize some of the uncertainty in the burden
estimates but does not provide an evaluation of the potential impact of
under- or overreporting of WBDOs or their associated severity
characteristics. The draft report includes recommendations for the
collection and reporting of additional outbreak information that would
improve the usefulness of the WBDO database for future disease burden
estimates.

II. How To Submit Technical Comments to EPA's E-Docket

    Submit your comments, identified by Docket ID No. EPA-ORD-2006-0666
by one of the following methods:
     http://www.regulations.gov: Follow the on-line instructions for

submitting comments.
     E-mail: ORD<EMAIL_ADDRESS>     Fax:<PHONE_NUMBER>.
     Mail: Office of Environmental Information (OEI) Docket
(Mail Code: 2822T), U.S. Environmental Protection Agency, 1200
Pennsylvania Ave., NW., Washington, DC 20460. The phone number is 202-
566-1752.
    If you provide comments by mail, please submit one unbound original
with pages numbered consecutively, and three copies. For attachments,
provide an index, number pages consecutively with the comments, and
submit an unbound original and three copies.
     Hand Delivery: The OEI Docket is located in the
Headquarters EPA Docket Center, EPA/DC; EPA West Building, 1301
Constitution Ave., NW., Washington, DC. The EPA Docket Center Public
Reading Room is open from 8:30 a.m. to 4:30 p.m., Monday through
Friday, excluding legal

holidays. The telephone number for the Public Reading Room is 202-566-
1744. Such deliveries are only accepted during the Docket's normal
hours of operation, and special arrangements should be made for
deliveries of boxed information.
    Instructions: Direct your comments to Docket ID No. EPA-ORD-2006-
0666. EPA's policy is that all comments received will be included in
the public docket without change and may be made available online at
http://www.regulations.gov, including any personal information provided,

unless the comment includes information claimed to be Confidential
Business Information (CBI) or other information whose disclosure is
restricted by statute. Do not submit information that you consider to
be CBI or otherwise protected through http://www.regulations.gov or e-mail.

The http://www.regulations.gov Web site is an ``anonymous access'' system,

which means EPA will not know your identity or contact information
unless you provide it in the body of your comment. If you send an e-
mail comment directly to EPA without going through http://www.regulations.gov,

your e-mail address will be automatically captured and included as part
of the comment that is placed in the public docket and made available
on the Internet. If you submit an electronic comment, EPA recommends
that you include your name and other contact information in the body of
your comment and with any disk or CD-ROM you submit. If EPA cannot read
your comment due to technical difficulties and cannot contact you for
clarification, EPA may not be able to consider your comment. Electronic
files should avoid the use of special characters, any form of
encryption, and be free of any defects or viruses. For additional
information about EPA's public docket visit the EPA Docket Center
homepage at http://www.epa.gov/epahome/dockets.htm.

    Docket: All documents in the docket are listed in the
http://www.regulations.gov index. Although listed in the index, some

information is not publicly available, e.g., CBI or other information
whose disclosure is restricted by statute. Certain other material, such
as copyrighted material, will be publicly available only in hard copy.
Publicly available docket materials are available either electronically
in http://www.regulations.gov or in hard copy at the OEI Docket in the EPA

Headquarters Docket Center.

    Note: The EPA Docket Center suffered damage due to flooding
during the last week of June 2006. The Docket Center is continuing
to operate. However, during the cleanup, there will be temporary
changes to Docket Center telephone numbers, addresses, and hours of
operation for people who wish to make hand deliveries or visit the
Public Reading Room to view documents. Consult EPA's Federal
Register notice at 71 FR 38147 (July 5, 2006) or the EPA Web site at
http://www.epa.gov/epahome/dockets.htm for current information on docket

operations, locations and telephone numbers. U.S. mail and the
procedures for submitting comments to http://www.regulations.gov are not

affected by the flooding and will remain the same.

    Dated: September 7, 2006.
Peter W. Preuss,
Director, National Center for Environmental Assessment.
[FR Doc. E6-15335 Filed 9-14-06; 8:45 am]

BILLING CODE 6560-50-P


[Federal Register Volume 87, Number 247 (Tuesday, December 27, 2022)]
[Notices]
[Pages 79336-79337]
[FR Doc No: 2022-28140]

=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF HOMELAND SECURITY

Federal Emergency Management Agency

[Docket ID FEMA-2014-0022]

Technical Mapping Advisory Council; Meeting

AGENCY: Federal Emergency Management Agency, DHS.

ACTION: Notice of Federal Advisory Committee Meeting.

-----------------------------------------------------------------------

SUMMARY: The Federal Emergency Management Agency (FEMA) Technical
Mapping Advisory Council (TMAC) will hold an in-person public meeting
with a virtual option on Monday, January 23, 2023, and Tuesday, January
24, 2023. The meeting will be open to the public in-person and via a
Microsoft Teams Video Communications link.

DATES: The TMAC will meet on Monday, January 23, 2023, and Tuesday,
January 24, 2023, from 8:00 a.m. to 5:00 p.m. Eastern Time (ET). Please
note that the meeting will close early if the TMAC has completed its
business.

ADDRESSES: The meeting will be held in-person at Michael Baker
International, 3601 Eisenhower Ave. Ste. 600, Alexandria, VA 22304, and
virtually using the following Microsoft Teams Video Communications link
(Monday Link: https://bit.ly/3FdGFXa; Tuesday Link: https://bit.ly/3VzEUbR). Members of the public who wish to attend the in-person or
virtual meeting must register in advance by sending an email to [email protected] (Attn: Brian Koper) by 5:00 p.m. ET on Thursday,
January 19, 2023. For information on services for individuals with
disabilities or to request special assistance at the meeting, contact
the person listed in the FOR FURTHER INFORMATION CONTACT caption below
as soon as possible.
    To facilitate public participation, members of the public are
invited to provide written comments on the issues to be considered by
the TMAC, as listed in the SUPPLEMENTARY INFORMATION caption below.
Associated meeting materials will be available upon request after
Tuesday, January 17, 2023. The draft 2022 TMAC Annual Report Outline
will be available for review after Tuesday, January 17, 2023. To
receive a copy of any relevant materials, please send the request to:
[email protected] (Attn: Brian Koper). Written comments to be
considered by the committee at the time of the meeting must be
submitted and received by Wednesday, January 18, 2023, 5:00 p.m. ET
identified by Docket ID FEMA-2014-0022, and submitted by one of the
following methods:
     Federal eRulemaking Portal: http://www.regulations.gov.
Follow the instructions for submitting comments.
     Email: Address the email to: [email protected].
Include the docket number in the subject line of the message. Include
name and contact information in the body of the email.
     Instructions: All submissions received must include the
words ``Federal Emergency Management Agency'' and the docket number for
this action. Comments received will be posted without alteration at
http://www.regulations.gov, including any personal information
provided. You may wish to review the Privacy & Security Notice via a
link on the homepage of www.regulations.gov.
     Docket: For docket access to read background documents or
comments received by the TMAC, go to http://www.regulations.gov and
search for the Docket ID FEMA-2014-0022.
    A public comment period will be held on Monday, January 23, 2023,
from 3:30 p.m. to 4:00 p.m. ET and Tuesday, January 24, 2023, from
11:45 a.m. to 12:15 p.m. ET. The public comment period will not exceed
30 minutes. Please note that the public comment period may end before
the time indicated, following the last call for comments. Contact the
individual listed below to register as a speaker by Wednesday, January
18, 2023, 5:00 p.m. ET. Please be prepared to submit a written version
of your public comment.
    FEMA is committed to ensuring all participants have equal access
regardless of disability status. If you require a reasonable
accommodation due to a disability to fully participate, please contact
the individual listed in the FOR FURTHER INFORMATION CONTACT caption as
soon as possible.

FOR FURTHER INFORMATION CONTACT: Brian Koper, Designated Federal
Officer for the TMAC, FEMA, 400 C Street SW, Washington, DC 20024,
telephone<PHONE_NUMBER>, and email [email protected]. The TMAC
website is: https://www.fema.gov/flood-maps/guidance-partners/technical-mapping-advisory-council

SUPPLEMENTARY INFORMATION: Notice of this meeting is given under the
Federal Advisory Committee Act, 5 U.S.C. App.
    In accordance with the Biggert-Waters Flood Insurance Reform Act of
2012, the TMAC makes recommendations to the FEMA Administrator on: (1)
how to improve, in a cost-effective manner, the (a) accuracy, general
quality, ease of use,

and distribution and dissemination of flood insurance rate maps and
risk data; and (b) performance metrics and milestones required to
effectively and efficiently map flood risk areas in the United States;
(2) mapping standards and guidelines for (a) flood insurance rate maps,
and (b) data accuracy, data quality, data currency, and data
eligibility; (3) how to maintain, on an ongoing basis, flood insurance
rate maps and flood risk identification; (4) procedures for delegating
mapping activities to State and local mapping partners; and (5) (a)
methods for improving interagency and intergovernmental coordination on
flood mapping and flood risk determination, and (b) a funding strategy
to leverage and coordinate budgets and expenditures across Federal
agencies. Furthermore, the TMAC is required to submit an annual report
to the FEMA Administrator that contains: (1) a description of the
activities of the Council; (2) an evaluation of the status and
performance of flood insurance rate maps and mapping activities to
revise and update Flood Insurance Rate Maps; and (3) a summary of
recommendations made by the Council to the FEMA Administrator.
    Agenda: The purpose of this meeting is for the TMAC members to
discuss and vote on the content of the 2023 TMAC Annual Report Outline.
Any related materials will be available upon request prior to the
meeting to provide the public an opportunity to review the materials.
The full agenda and related meeting materials will be available upon
request by Tuesday, January 17, 2023. To receive a copy of any relevant
materials, please send the request to: [email protected] (Attn:
Brian Koper).

Michael M. Grimm,
Assistant Administrator for Risk Management, Federal Emergency
Management Agency.
[FR Doc. 2022-28140 Filed 12-23-22; 8:45 am]
BILLING CODE 9110-12-P